주요 효모균과 사상형 진균의 항진균제 내성현황

키워드

참고문헌 (33)

1. Arikan S, "Antifungal agents in Manual of clinical microbiology", pp.1949~ (2008), ASM Press
2. Kanafani ZA, "Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact", Clin Infect Dis, 46, pp.120~128 (2008)
3. Espinel-Ingroff A, "Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi", Rev Iberoam Micol, 25, pp.101~106 (2008)
4. Pfaller MA, "Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus", J Clin Microbiol, 42, pp.4419~4431 (2004)
5. Sanglard D, "Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences", Lancet Infect Dis, 2, pp.73~85 (2002)
6. 이진솔, "Species Distribution and Susceptibility to Azole Antifungals of Candida Bloodstream Isolates from Eight University Hospitals in Korea", Yonsei Medical Journal, 48(5), pp.779~786 (2007), 연세대학교의과대학
7. Shin JH, "Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia", J Clin Microbiol, 45, pp.2385~2391 (2007)
8. Sanguinetti M, "Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance", Antimicrob Agents Chemother, 49, pp.668~679 (2005)
9. Pfaller MA, "Global Antifungal Surveillance Study. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing", J Clin Microbiol, 45, pp.1735~1745 (2007)
10. Pfaller MA, "Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing", Clin Microbiol Rev, 19, pp.435~447 (2006)
11. Pfaller MA, "Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002", J Clin Microbiol, 42, pp.3142~3146 (2004)
12. Kim SH, "The relationship between antifungal usage and antifungal susceptibility in clinical isolates of Candida: a multicenter Korean study", Med Mycol, 47, pp.296~304 (2009)
13. Pfaller MA, "Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000", Antimicrob Agents Chemother, 46, pp.1032~1037 (2002)
14. 신종희, "한국인의 임상분리 아스페르길루스 균주에 대한 보리코나졸의 생체외 감수성", 대한의진균학회지, 9(3), pp.166~173 (2004), 대한의진균학회1
15. Shao PL, "Recent advances and challenges in the treatment of invasive fungal infections", Int J Antimicrob Agents, 30, pp.487~495 (2007)
16. Siwek GT, "Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis", Diagn Microbiol Infect Dis, 55, pp.209~212 (2006)
17. 박지영, "CLSI 액체배지 미량희석법, Etest 및 Minimum Fungicidal Concentration 검사에 의한 국내 혈액에서 분리된 효모균의 시험관 내 Amphotericin B 내성 성적", The Korean Journal of Laboratory Medicine, 28(5), pp.346~352 (2008), 대한진단검사의학회
18. Pappas PG, "Guidelines for treatment of candidiasis", Clin Infect Dis, 38, pp.161~189 (2004)
19. Kim MN, "Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features", Clin Infect Dis, 48, pp.e57~61 (2009)
20. Arikan S, "Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates", Diagn Microbiol Infect Dis, 43, pp.107~111 (2002)
21. Messer SA, "International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003)", J Clin Microbiol, 44, pp.1782~1787 (2006), 1782-7,2006
22. Balajee SA, "Aspergillus lentulus sp. nov., a new sibling species of A", fumigatus, 4, pp.625~632 (2005)
23. Lass-Flörl C, "In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis", J Antimicrob Chemother, 42, pp.497~502 (1998)
24. Espinel-Ingroff A, "Susceptibility test methods: yeasts and filamentous fingi in Manual of clinical microbiology", pp.1972~ (2008), ASM Press
25. Cheung C, "Development of candidemia on caspofungin therapy: a case report", Infection, 34, pp.345~348 (2006)
26. Pfaller MA, "Epidemiology of invasive candidiasis: a persistent public health problem", Clin Microbiol Rev, 20, pp.133~163 (2007)
27. 최현우, "칸디다 균종의 Caspofungin과 Micafungin에 대한 생체 외 감수성 성적", The Korean Journal of Laboratory Medicine, 26(4), pp.275~281 (2006), 대한진단검사의학회
28. Balashov SV, "Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1", Antimicrob Agents Chemother, 50, pp.2058~2063 (2006)
29. Matsue K, "Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin", Clin Infect Dis, 42, pp.753~757 (2006)
30. Clinical and Laboratory Standards Institute, "Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi.2nd ed. Approved standard M38-A2, Villanova, Pa., Clinical and Laboratory Standards Institute, 2008", ~
31. 이진솔, "임상검체에서 분리된 아스페르길루스 균주의 Echinocandin에 대한 생체 외 감수성", Infection and Chemotherapy, 39(3), pp.151~158 (2007), 대한감염학회
32. Stevens DA, "Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations", Antimicrob Agents Chemother, 48, pp.3407~3411 (2004)
33. Stevens DA, "Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin", Antimicrob Agents Chemother, 50, pp.3160~3161 (2006)

관련 논문AI추천